In addition to the patent, Revive also gets the intellectual and work property derived from DiagnaMed’s research activities ...
"Receiving orphan drug designation from the FDA is a significant milestone for DiagnaMed and validates the promise of molecular hydrogen as a potential treatment for ALS. We are excited to partner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback